Veracyte (VCYT) Price & Analysis

Compare

534 Followers

VCYT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$22.61 - $47.32

Previous CloseN/A

Volume253.49K

Average Volume (3M)982.36K

Market Cap

$2.63B

Enterprise Value$1.85B

Total Cash (Recent Filing)$320.72M

Total Debt (Recent Filing)$50.65M

Price to Earnings (P/E)100.5

Beta1.56

Next Earnings

Nov 11, 2025

EPS Estimate

0.32

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.44

Shares Outstanding78,671,585

10 Day Avg. Volume988,649

30 Day Avg. Volume982,356

Financial Highlights & Ratios

PEG Ratio-0.96

Price to Book (P/B)2.58

Price to Sales (P/S)6.79

P/FCF Ratio47.47

Enterprise Value/Market Cap0.70

Enterprise Value/Revenue3.86

Enterprise Value/Gross Profit5.73

Enterprise Value/Ebitda31.47

Forecast

1Y Price Target

$37.75

Price Target Upside12.89% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Financial PerformanceStrong base business momentum/margins and solid execution, along with best-in-class margins and a strong balance sheet deserves credit.

Guidance And ExpectationsManagement provided 2025 revenue guidance that was above consensus and raised their 2025 Testing revenue and adjusted EBITDA margin guidance.

Revenue GrowthDecipher momentum continues with +24% y/y revenue growth, while Afirma also saw solid performance in the quarter.

Bears Say

Market DynamicsThe upside from these latter two dynamics is unlikely to be reflected in the numbers until the 2027+ timeframe and the rapidly evolving competitive / IP dynamics in the MRD market bear watching.

Regulatory ChallengesNasal Swab reimbursement is unlikely to fall in place until 2028+ at the earliest in light of the NIGHTINGALE enrollment expected to complete in 3Q25.

Veracyte News

Veracyte reports Phase 3 STAMPEDE trial finding published in Cell

Veracyte (VCYT) and University College London announced that data published online in Cell show that the Decipher Prostate...

1M ago

VCYT

Veracyte meets targeted enrollment for NIGHTINGALE trial

Veracyte (VCYT) announced it has met its targeted enrollment for the NIGHTINGALE trial, which aims to evaluate the...

1M ago

VCYT

Veracyte management to meet with Craig-Hallum

Meeting to be held in Denver on August 19 hosted by Craig-Hallum. Published first on TheFly – the...

1M ago

VCYT

Cautious Outlook on Veracyte: Sell Rating Amid Market Uncertainties and Valuation Concerns

Yuko Oku, an analyst from Morgan Stanley, maintained the Sell rating on Veracyte. The associated price target is...

2M ago

VCYT

Veracyte price target lowered to $28 from $29 at Morgan Stanley

Morgan Stanley analyst Tejas Savant lowered the firm’s price target on Veracyte (VCYT) to $28 from $29 and...

2M ago

VCYT

Veracyte’s Strong Clinical Evidence and Market Growth Justify Buy Rating

Puneet Souda, an analyst from Leerink Partners, maintained the Buy rating on Veracyte. The associated price target is...

2M ago

VCYT

Veracyte Inc’s Earnings Call Highlights Robust Growth and Strategic Milestones

Veracyte Inc (($VCYT)) has held its Q2 earnings call. Read on for the main highlights of the call....

2M ago

VCYT

Veracyte’s Strong Financial Performance and Promising Growth Prospects Justify Buy Rating

William Blair analyst Andrew Brackmann has maintained their bullish stance on VCYT stock, giving a Buy rating today....

2M ago

VCYT

Veracyte’s Strong Financial Performance and Growth Prospects Justify Buy Rating

Needham analyst Michael Matson has reiterated their bullish stance on VCYT stock, giving a Buy rating on August...

2M ago

VCYT

Veracyte Reports Strong Q2 2025 Revenue Growth

Veracyte Inc ( ($VCYT) ) has released its Q2 earnings. Here is a breakdown of the information Veracyte...

2M ago

VCYT

Veracyte sees FY25 revenue $477M-$483M, consensus $491.92M

The company is raising full-year 2025 testing revenue guidance to $477 million to $483 million, or 14% to...

2M ago

VCYT

Veracyte reports Q2 EPS 44c, consensus 30c

Reports Q2 revenue $130.164M, consensus $120.9M. “Testing growth continues to exceed our expectations, driven by Decipher which achieved...

2M ago

VCYT

BMNR, VCYT, ZG: Cathie Wood Buys $15M More of Ethereum-Linked Bitmine

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) poured millions of dollars into the cryptocurrency market on July 29, as the prices of...

2M ago

XYZ

CRSP, ABSI, IRDM: Cathie Wood Offloads $16.4M of CRISPR Therapeutics Stock, Buys Absci and Iridium

Ace hedge fund manager Cathie Wood made some interesting trades on July 25, according to ARK Invest’s daily...

2M ago

ABSI

ARKG

VCYT FAQ

What was Veracyte Inc’s price range in the past 12 months?

Veracyte Inc lowest stock price was $22.61 and its highest was $47.32 in the past 12 months.

What is Veracyte Inc’s market cap?

Veracyte Inc’s market cap is $2.63B.

When is Veracyte Inc’s upcoming earnings report date?

Veracyte Inc’s upcoming earnings report date is Nov 11, 2025 which is in 44 days.

How were Veracyte Inc’s earnings last quarter?

Veracyte Inc released its earnings results on Aug 06, 2025. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.279 by $0.161.

Is Veracyte Inc overvalued?

According to Wall Street analysts Veracyte Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Veracyte Inc pay dividends?

Veracyte Inc does not currently pay dividends.

What is Veracyte Inc’s EPS estimate?

Veracyte Inc’s EPS estimate is 0.32.

How many shares outstanding does Veracyte Inc have?

Veracyte Inc has 78,671,585 shares outstanding.

What happened to Veracyte Inc’s price movement after its last earnings report?

Veracyte Inc reported an EPS of $0.44 in its last earnings report, beating expectations of $0.279. Following the earnings report the stock price went up 15.478%.

Which hedge fund is a major shareholder of Veracyte Inc?

Currently, no hedge funds are holding shares in VCYT

Veracyte Stock Smart Score

Underperform

Fundamentals

Return on Equity

2.24%

Trailing 12-Months

Asset Growth

8.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Veracyte Inc

Veracyte, Inc. is a genomic diagnostics company that focuses on improving patient outcomes through the development and commercialization of diagnostic tests for patients with cancer and other diseases. The company operates primarily in the healthcare sector, offering innovative solutions that enhance the accuracy of diagnoses and help physicians make informed treatment decisions. Veracyte's core products include its proprietary genomic tests, such as the Afirma Genomic Sequencing Classifier for thyroid cancer and the Percepta Genomic Sequencing Classifier for lung cancer, which are designed to reduce unnecessary surgeries and improve patient management.

Veracyte (VCYT) Earnings & Revenues

Historic Earnings Reports

VCYT Company Deck

VCYT Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reveals a positive outlook for Veracyte, with strong revenue growth driven by Decipher and Afirma tests, successful launch of new products, and an impressive cash position. However, there are challenges such as a decline in product revenue and the impact of the Veracyte SAS sale on future margins.View all VCYT earnings summaries

VCYT Stock 12 Month Forecast

Average Price Target

$37.75

▲(12.89% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","46":"$46","25.75":"$25.8","32.5":"$32.5","39.25":"$39.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,25.75,32.5,39.25,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.64,25.283076923076923,26.926153846153845,28.56923076923077,30.212307692307693,31.855384615384615,33.49846153846154,35.14153846153846,36.784615384615385,38.42769230769231,40.07076923076923,41.713846153846156,43.35692307692308,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.64,24.725384615384616,25.810769230769232,26.896153846153847,27.981538461538463,29.06692307692308,30.152307692307694,31.237692307692306,32.323076923076925,33.40846153846154,34.49384615384616,35.57923076923077,36.66461538461539,{"y":37.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.64,23.975384615384616,24.310769230769232,24.646153846153847,24.981538461538463,25.31692307692308,25.652307692307694,25.987692307692306,26.323076923076922,26.658461538461538,26.993846153846153,27.32923076923077,27.664615384615384,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.13,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.95,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.13,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.31,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.12,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.32,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.64,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >